Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study)

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 5, 2006, Pages 1090-1093

  Djabarouti, Sarah ^a,b   Breilh, Dominique ^a,b   Pellegrin, Isabelle ^b   Lavit, Michel ^d   Camou, Fabrice ^b   Caubet, Olivier ^b   Fleury, Hervé ^c   Saux, Marie Claude ^a,b   Pellegrin, Jean Luc ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c HÔPITAL PELLEGRIN   (France)

^d SERVICE DE PNEUMOLOGIE   (France)

Author keywords

Drug efflux; Drug metabolism; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

EFAVIRENZ; OXAZINE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; BLOOD; COHORT ANALYSIS; FEMALE; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 39049180393     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl348     Document Type: Article

References (10)

1. Molina JM, Journot V, Morand-Joubert et a. Simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-1-Infected adults with viral suppression receiving a protease inhibitor-based regimen: A randomized trial. Clin Infect Dis 2005; 191: 830-9.
2. Marzolini C, Telenti A, Descostered LA et a. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-5.
3. Csajka C, Marzolini C, Fattinger K et a. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003; 73 20-30.
4. Rouzes A, Berthoin K, Xuereb F et a. Simultaneous determination of the antiretroviral agents: Amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 813: 209-16.
5. Rotger M, Colombo S, Furrer H et a. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15: 1-5.
6. Chandler B, Almond L, Ford J et a. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 2003; 33: 551-6.
7. Fellay J, Marzolini C, Meaden ER et a. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 2002; 359: 30-6.
8. Almond LM, Hoggard PG, Edirisinghe D et a. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 2005; 56: 738-44.
9. Owen A, Khoo SH. Intracellular pharmacokinetics of antiretroviral agents. J HIV Ther 2004; 9: 97-101.
10. Haas DW, Smeaton LM, Shafer RW et a. Pharmacogenetics of long-term response to antiretroviral regimens containing efavirenz and/or nelfinavir: An Adult Aids Clinical Trials Group Study. J Infect Dis 2005; 192: 1931-42.